Ultragenyx today announced a Phase 1/2 study of UX003 for MPS VII

Ultragenyx announced a Phase 1/2 study of UX003 for MPS VII. Read the full press release. Read the Q&A with Dr. Emil Kakkis.

This entry was posted in News. Bookmark the permalink.

Comments are closed.